Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

miR-3174 Contributes to Apoptosis and Autophagic Cell Death Defects in Gastric Cancer Cells by Targeting ARHGAP10.

Li B, Wang L, Li Z, Wang W, Zhi X, Huang X, Zhang Q, Chen Z, Zhang X, He Z, Xu J, Zhang L, Xu H, Zhang D, Xu Z.

Mol Ther Nucleic Acids. 2017 Dec 15;9:294-311. doi: 10.1016/j.omtn.2017.10.008. Epub 2017 Oct 17.

2.

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts.

Brana I, Pham NA, Kim L, Sakashita S, Li M, Ng C, Wang Y, Loparco P, Sierra R, Wang L, Clarke BA, Neel BG, Siu LL, Tsao MS.

Oncotarget. 2017 Jul 8;8(49):84659-84670. doi: 10.18632/oncotarget.19109. eCollection 2017 Oct 17.

3.

Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Avril S.

Pathologe. 2017 Nov;38(Suppl 2):180-191. doi: 10.1007/s00292-017-0375-9. Review.

PMID:
29119232
4.

MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression.

Li B, Wang W, Li Z, Chen Z, Zhi X, Xu J, Li Q, Wang L, Huang X, Wang L, Wei S, Sun G, Zhang X, He Z, Zhang L, Zhang D, Xu H, El-Rifai W, Xu Z.

Cancer Lett. 2017 Dec 1;410:212-227. doi: 10.1016/j.canlet.2017.09.035. Epub 2017 Sep 28.

5.

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX.

Clin Cancer Res. 2017 Nov 1;23(21):6580-6591. doi: 10.1158/1078-0432.CCR-17-0033. Epub 2017 Aug 14.

PMID:
28808038
6.

Prodelphinidins isolated from Chinese bayberry leaves induces apoptosis via the p53-dependent signaling pathways in OVCAR-3 human ovarian cancer cells.

Fu Y, Ye X, Lee M, Rankin G, Chen YC.

Oncol Lett. 2017 May;13(5):3210-3218. doi: 10.3892/ol.2017.5813. Epub 2017 Mar 6.

7.

High BIM mRNA levels are associated with longer survival in advanced gastric cancer.

Wu N, Huang Y, Zou Z, Gimenez-Capitan A, Yu L, Hu W, Zhu L, Sun X, Sanchez JJ, Guan W, Liu B, Rosell R, Wei J.

Oncol Lett. 2017 Mar;13(3):1826-1834. doi: 10.3892/ol.2017.5660. Epub 2017 Feb 1.

8.

Chemoresistance and targeted therapies in ovarian and endometrial cancers.

Brasseur K, Gévry N, Asselin E.

Oncotarget. 2017 Jan 17;8(3):4008-4042. doi: 10.18632/oncotarget.14021. Review.

9.

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.

Dai Y, Jin S, Li X, Wang D.

Oncotarget. 2017 Jan 3;8(1):1354-1368. doi: 10.18632/oncotarget.13817.

10.

Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, Powell MA, Backes FJ, Mathews CA, Pearl ML, Secord AA, Peace DJ, Mutch DG, Creasman WT, Kim JJ.

Cancer. 2017 Apr 1;123(7):1144-1155. doi: 10.1002/cncr.30477. Epub 2016 Dec 7.

PMID:
27926776
11.

Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.

Wang S, Jiang L, Han Y, Chew SH, Ohara Y, Akatsuka S, Weng L, Kawaguchi K, Fukui T, Sekido Y, Yokoi K, Toyokuni S.

Oncotarget. 2016 Oct 25;7(43):69565-69578. doi: 10.18632/oncotarget.11829.

12.

Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.

Hosain SB, Khiste SK, Uddin MB, Vorubindi V, Ingram C, Zhang S, Hill RA, Gu X, Liu YY.

Oncotarget. 2016 Sep 13;7(37):60575-60592. doi: 10.18632/oncotarget.11169.

13.

The important application of thioridazine in the endometrial cancer.

Meng Q, Sun X, Wang J, Wang Y, Wang L.

Am J Transl Res. 2016 Jun 15;8(6):2767-75. eCollection 2016.

14.

Anti-apoptotic brain and reproductive organ-expressed proteins enhance cisplatin resistance in lung cancer cells via the protein kinase B signaling pathway.

Li Y, Qi K, Zu L, Wang M, Wang Y, Zhou Q.

Thorac Cancer. 2016 Mar;7(2):190-8. doi: 10.1111/1759-7714.12313. Epub 2015 Oct 20.

15.

Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells.

Suman S, Das TP, Sirimulla S, Alatassi H, Ankem MK, Damodaran C.

Oncotarget. 2016 Mar 22;7(12):13854-64. doi: 10.18632/oncotarget.7351.

16.

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.

Chen J, Wang L, Tang Y, Gong G, Liu L, Chen M, Chen Z, Cui Y, Li C, Cheng X, Qi L, Zu X.

J Exp Clin Cancer Res. 2016 Jan 6;35:2. doi: 10.1186/s13046-015-0282-y.

17.
18.

Caspase-3 feedback loop enhances Bid-induced AIF/endoG and Bak activation in Bax and p53-independent manner.

Guo W, Zhang Y, Ling Z, Liu X, Zhao X, Yuan Z, Nie C, Wei Y.

Cell Death Dis. 2015 Oct 15;6:e1919. doi: 10.1038/cddis.2015.276.

19.

The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes.

Davidescu M, Macchioni L, Scaramozzino G, Cristina Marchetti M, Migliorati G, Vitale R, Corcelli A, Roberti R, Castigli E, Corazzi L.

Sci Rep. 2015 Sep 21;5:14343. doi: 10.1038/srep14343.

20.

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.

Salim H, Zong D, Hååg P, Novak M, Mörk B, Lewensohn R, Lundholm L, Viktorsson K.

BMC Cancer. 2015 Sep 9;15:628. doi: 10.1186/s12885-015-1635-9.

Supplemental Content

Support Center